Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma

European Journal of Haematology

Volumn 89, Issue 4, 2012, Pages 328-335

  Puig, Noemí ^a   Sarasquete, María E ^a,b   Alcoceba, Miguel ^a,b   Balanzategui, Ana ^a   Chillón, María C ^a,b   Sebastián, Elena ^a   Díaz, Marcos G ^a,b   San Miguel, Jesús F ^a,b   García Sanz, Ramón ^a,b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b Centro de Investigacion del Cancer   (Spain)

Author keywords

Immunoglobulin kappa gene; Kappa deleting element; Minimal residual disease; Multiple myeloma; Real time quantitative PCR

Indexed keywords

GENOMIC DNA; IMMUNOGLOBULIN KAPPA CHAIN;

ARTICLE; BONE MARROW BIOPSY; CLINICAL ASSESSMENT; GENE REARRANGEMENT; HUMAN; HUMAN CELL; IMMUNOGLOBULIN GENE; INCIDENCE; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REAL TIME QUANTITATIVE POLYMERASE CHAIN REACTION;

BASE SEQUENCE; DNA PRIMERS; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; INTRONS; MULTIPLE MYELOMA; MUTATION; NEOPLASM, RESIDUAL; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84866380001     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12000     Document Type: Article

References (22)

1. Bladé J, Rosiñol L, Sureda A, et al. High-dose therapy intensification versus continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005;106:3755-9.
2. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-83.
3. Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007;25:2434-41.
4. Ocio EM, Mateos MV, Maiso P, Pandiella A, San-Miguel JF. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol 2008;9:1157-65.
5. Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011;117:4691-5.
6. Paiva B, Vidriales MB, Cervero J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008;112:4017-23.
7. Martinez-Sanchez P, Montejano L, Sarasquete ME, et al. Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achieving molecular response. Br J Haematol 2008;142:766-74.
8. Sarasquete ME, Garcia-Sanz R, Gonzalez D, et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica 2005;90:1365-72.
9. Ladetto M, Pagliano G, Ferrero S, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 2010;28:2077-84.
10. Rawstron AC, Davies FE, Dasgupta R, Ashcroft AJ, Patmore R, Drayson MT, Owen RG, Jack AS, Child JA, Morgan GJ. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 2002;100:3095-100.
11. Putkonen M, Kairisto V, Juvonen V, Pelliniemi TT, Rauhala A, Itälä-Remes M, Remes K. Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma. Eur J Haematol 2010;85:416-23.
12. Gonzalez D, Gonzalez M, Alonso ME, López-Pérez R, Balanzategui A, Chillón MC, Silva M, García-Sanz R, San Miguel JF. Incomplete DJH rearrangements as a novel tumor target for minimal residual disease quantitation in multiple myeloma using real-time PCR. Leukemia 2003;17:1051-7.
13. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003;17:2257-317.
14. van der Velden V, Willemse MJ, van der Schoot CE, Hählen K, van Wering ER, van Dongen JJ. Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR. Leukemia 2002;16:928-36.
15. Brochet X, Lefranc MP, Giudicelli V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res 2008;36:W503-8.
16. van der Velden V, Cazzaniga G, Schrauder A, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007;21:604-11.
17. Gonzalez D, Balanzategui A, Garcia-Sanz R, García-Sanz R, Gutiérrez N, Seabra C, van Dongen JJ, González M, San Miguel JF. Incomplete DJH rearrangements of the IgH gene are frequent in multiple myeloma patients: immunobiological characteristics and clinical implications. Leukemia 2003;17:1398-403.
18. Gonzalez D, Gonzalez M, Balanzategui A, Sarasquete ME, López-Pérez R, Chillón MC, García-Sanz R, San Miguel JF. Molecular characteristics and gene segments usage in IGH gene rearrangements in multiple myeloma. Haematologica 2005;90:906-13.
19. Garcia-Sanz R, Lopez-Perez R, Langerak AW, et al. Heteroduplex PCR analysis of rearranged immunoglobulin genes for clonality assessment in multiple myeloma. Haematologica 1999;84:328-35.
20. Hadzidimitriou A, Stamatopoulos K, Belessi C, et al. Immunoglobulin genes in multiple myeloma: expressed and non-expressed repertoires, heavy and light chain pairings and somatic mutation patterns in a series of 101 cases. Haematologica 2006;91:781-7.
21. Gonzalez D, van der Burg M, Garcia-Sanz R, Fenton JA, Langerak AW, González M, van Dongen JJ, San Miguel JF, Morgan GJ. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 2007;110:3112-21.
22. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010;115:3206-14.